350 related articles for article (PubMed ID: 31302855)
1. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers.
Heemskerk-Gerritsen BAM; Jager A; Koppert LB; Obdeijn AI; Collée M; Meijers-Heijboer HEJ; Jenner DJ; Oldenburg HSA; van Engelen K; de Vries J; van Asperen CJ; Devilee P; Blok MJ; Kets CM; Ausems MGEM; Seynaeve C; Rookus MA; Hooning MJ
Breast Cancer Res Treat; 2019 Oct; 177(3):723-733. PubMed ID: 31302855
[TBL] [Abstract][Full Text] [Related]
2. Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis.
Heemskerk-Gerritsen BA; Menke-Pluijmers MB; Jager A; Tilanus-Linthorst MM; Koppert LB; Obdeijn IM; van Deurzen CH; Collée JM; Seynaeve C; Hooning MJ
Ann Oncol; 2013 Aug; 24(8):2029-35. PubMed ID: 23576707
[TBL] [Abstract][Full Text] [Related]
3. Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis.
De Felice F; Marchetti C; Musella A; Palaia I; Perniola G; Musio D; Muzii L; Tombolini V; Benedetti Panici P
Ann Surg Oncol; 2015 Sep; 22(9):2876-80. PubMed ID: 25808098
[TBL] [Abstract][Full Text] [Related]
4. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
5. Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction.
Stjepanovic N; Villacampa G; Nead KT; Torres-Esquius S; Melis GG; Nathanson KL; Teule A; Brunet J; Y Cajal TR; Llort G; Dienstmann R; Rue M; Domchek SM; Balmaña J
Eur J Cancer; 2020 Jun; 132():53-60. PubMed ID: 32325420
[TBL] [Abstract][Full Text] [Related]
6. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
[TBL] [Abstract][Full Text] [Related]
8. Post-mastectomy surveillance of BRCA1/BRCA2 mutation carriers: Outcomes from a specialized clinic for high-risk breast cancer patients.
Kanana N; Ben David MA; Nissan N; Yagil Y; Shalmon A; Halshtok O; Gotlieb M; Faermann R; Klang E; Samoocha D; Yassin M; Davidson T; Zippel D; Madorsky Feldman D; Friedman E; Kaidar-Person O; Sklair Levy M
Breast J; 2021 May; 27(5):441-447. PubMed ID: 33576117
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction.
Heemskerk-Gerritsen BA; Seynaeve C; van Asperen CJ; Ausems MG; Collée JM; van Doorn HC; Gomez Garcia EB; Kets CM; van Leeuwen FE; Meijers-Heijboer HE; Mourits MJ; van Os TA; Vasen HF; Verhoef S; Rookus MA; Hooning MJ;
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25788320
[TBL] [Abstract][Full Text] [Related]
10. Risk-reducing mastectomy for the prevention of primary breast cancer.
Carbine NE; Lostumbo L; Wallace J; Ko H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD002748. PubMed ID: 29620792
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy.
Michaelson-Cohen R; Gabizon-Peretz S; Armon S; Srebnik-Moshe N; Mor P; Tomer A; Levy-Lahad E; Paluch-Shimon S
Eur J Cancer; 2021 May; 148():95-102. PubMed ID: 33743487
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients.
van den Broek AJ; Schmidt MK; van 't Veer LJ; Oldenburg HSA; Rutgers EJ; Russell NS; Smit VTHBM; Voogd AC; Koppert LB; Siesling S; Jobsen JJ; Westenend PJ; van Leeuwen FE; Tollenaar RAEM
Ann Surg; 2019 Aug; 270(2):364-372. PubMed ID: 29727326
[TBL] [Abstract][Full Text] [Related]
13. Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.
Chai X; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Tung N; Weitzel JN; Couch FJ; Hulick PJ; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Blum JL; Domchek SM; Chen J; Rebbeck TR
Breast Cancer Res Treat; 2014 Nov; 148(2):397-406. PubMed ID: 25311111
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age.
Drooger J; Akdeniz D; Pignol JP; Koppert LB; McCool D; Seynaeve CM; Hooning MJ; Jager A
Breast Cancer Res Treat; 2015 Nov; 154(1):171-80. PubMed ID: 26467044
[TBL] [Abstract][Full Text] [Related]
15. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer.
Kaas R; Verhoef S; Wesseling J; Rookus MA; Oldenburg HS; Peeters MJ; Rutgers EJ
Ann Surg; 2010 Mar; 251(3):488-92. PubMed ID: 20134318
[TBL] [Abstract][Full Text] [Related]
17. The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer.
Narod SA
Breast Cancer Res Treat; 2011 Jul; 128(2):581-3. PubMed ID: 21455666
[TBL] [Abstract][Full Text] [Related]
18. Uptake of bilateral-risk-reducing-mastectomy: Prospective analysis of 7195 women at high-risk of breast cancer.
Evans DG; Gandhi A; Wisely J; Clancy T; Woodward ER; Harvey J; Highton L; Murphy J; Barr L; Howell SJ; Lalloo F; Harkness EF; Howell A
Breast; 2021 Dec; 60():45-52. PubMed ID: 34464846
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic.
Heemskerk-Gerritsen BA; Brekelmans CT; Menke-Pluymers MB; van Geel AN; Tilanus-Linthorst MM; Bartels CC; Tan M; Meijers-Heijboer HE; Klijn JG; Seynaeve C
Ann Surg Oncol; 2007 Dec; 14(12):3335-44. PubMed ID: 17541692
[TBL] [Abstract][Full Text] [Related]
20. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.
Gamble C; Havrilesky LJ; Myers ER; Chino JP; Hollenbeck S; Plichta JK; Kelly Marcom P; Shelley Hwang E; Kauff ND; Greenup RA
Ann Surg Oncol; 2017 Oct; 24(11):3116-3123. PubMed ID: 28699130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]